RSV Vaccine for Rare Kid Illnesses Gets Speedy FDA Nod
Published Date: 4/16/2026
Notice
Summary
The FDA just gave the green light to MRESVIA, a vaccine for a rare but serious lung virus in kids, using a special priority review voucher. This means faster approval for important medicines that help rare pediatric diseases, speeding up access for families who need them. The approval was finalized on June 12, 2025, marking a big win for rare disease treatments and encouraging more innovation.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Approves MRESVIA Using Rare Pediatric Voucher
If you are a parent of a child affected by the targeted illness, the FDA approved MRESVIA (Respiratory Syncytial Virus Vaccine) via a Biologics License Application supplement on June 12, 2025. The FDA determined this approval redeemed a Rare Pediatric Disease Priority Review Voucher and published notice of the approval.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in